



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/509,799	07/15/2005	Yoshiki Sawa	Anges-5	3108
1473	7590	01/30/2007	EXAMINER	
FISH & NEAVE IP GROUP ROPES & GRAY LLP 1211 AVENUE OF THE AMERICAS NEW YORK, NY 10036-8704			HILL, KEVIN KAI	
ART UNIT		PAPER NUMBER		
1633				
SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE		
31 DAYS	01/30/2007	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No.	Applicant(s)
	10/509,799	SAWA ET AL.
	Examiner	Art Unit
	Kevin K. Hill, Ph.D.	1633

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on ____.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-20 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) 1-20 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date. ____.
3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 5) Notice of Informal Patent Application
6) Other: ____.

Election/Restrictions

Claims 1-20, drawn to a composition comprising at least one NF-kB decoy and a pharmaceutically acceptable carrier, a method for treating or preventing a disease or disorder associated with an ischemic condition of a brain, and a method for carrying out gene transfection in a brain.

A species restriction is required under 35 U.S.C. 121 and 372. This application contains claims, Claims 1, 5, 7, 9, 11, 15, 17 and 19, directed to more than one species of decoys. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1. In response to the restriction requirement, Applicant must further elect a single decoy species, wherein the decoy is, specifically:

- i) a non-NF-kB decoy, presently embraced in Claims 7 and 17, or
- ii) an NF-kB decoy, as recited in Claims 1, 5, 9, 11, 15 and 19.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

In the instant application, the International Preliminary Examination Report has documented that the decoy of Group I does not appear to be novel since it is described in the prior art (Takayoshi et al, 2001; * of record).

A search for an undisclosed decoy composition would not be co-extensive with a search for an NF-kB decoy. Further, a reference rendering an NF-kB decoy as anticipated or obvious over the prior art would not necessarily also render an undisclosed decoy composition as anticipated or obvious over the prior art. Because these inventions are distinct for reasons given above, and because a search of one does not necessarily overlap with that of another, it would be unduly burdensome for the examiner to search and examine all the subject matter being sought in the presently pending claims and thus, restriction for examination purposes as indicated is proper.

Applicant is required to elect a single named decoy species as listed in the cited claims to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

The claims are deemed to correspond to the species listed above in the following manner:

Claims 7 and 17, and claims dependent therefrom correspond to all the species listed above. The following claim(s) are generic: Claims 7 and 17.

A species restriction is required under 35 U.S.C. 121 and 372. This application contains claims, Claims 2-3 and 12-13, directed to more than one species of diseases and disorders. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1. In response to the restriction requirement, Applicant must further elect a single disease or disorder species from the list consisting of those diseases and disorders recited in Claims 2-3 and 12-13.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

The species are drawn to multiple diseases and disorders that are physiologically distinct and require distinctly different clinical treatments. Given the breadth of the claimed diseases and disorders, a search for all possible species imposes an exceptional burden on the Office. As the technical feature, an NF- κ B decoy for use in treating a disease, linking the members do not constitute a special technical feature as defined by PCT Rule 13.2, particularly since each of the species does not share a substantially common structural feature or function, the requirement for unity of invention is not fulfilled.

A search for subarachnoid hemorrhage would not be co-extensive with a search for brain tumor. Further, a reference rendering head injury as anticipated or obvious over the prior art would not necessarily also render incontinence of urine as anticipated or obvious over the prior

Art Unit: 1633

art. Similarly, a finding that dementia was novel and unobvious over the prior art would not necessarily extend to a finding that motor disorders was also novel and unobvious over the prior art. Because these inventions are distinct for reasons given above, and because a search of one does not necessarily overlap with that of another, it would be unduly burdensome for the examiner to search and examine all the subject matter being sought in the presently pending claims and thus, restriction for examination purposes as indicated is proper.

Applicant is required to elect a single named disease or disorder species as listed in the cited claims to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

The claims are deemed to correspond to the species listed above in the following manner:

Claims 1 and 11, and claims dependent therefrom correspond to all the species listed above. The following claim(s) are generic: Claims 1 and 11.

Should Applicant traverse on the ground that the species are not patentably distinct, Applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Should Applicant add or amend the claims of an elected invention to introduce subject matter from a non-elected invention for which the above stated group restriction(s) and/or species election(s) is(are) required, then Applicant is required to make the appropriate elections set forth below in accordance with the subject matter recited in the newly added or amended claims.



Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after

the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin K. Hill, Ph.D. whose telephone number is 571-272-8036. The examiner can normally be reached on Monday through Friday, between 9:00am-6:00pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph T. Woitach can be reached on 571-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Q. JANICE LI, M.D.
PRIMARY EXAMINER